Exploring red cell distribution width as a biomarker for treatment efficacy in home mechanical ventilation.
Biological marker
Chronic respiratory failure
Home mechanical ventilation
Red cell distribution width
Treatment efficacy
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
30 Mar 2022
30 Mar 2022
Historique:
received:
05
07
2021
accepted:
23
03
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
2
4
2022
Statut:
epublish
Résumé
With the growing practice of home mechanical ventilation, there is a need to identify biological markers for adequate follow-up. Red cell distribution width (RDW) is a promising candidate because it is convenient, objective and may reflect treatment effect over a long period of time. The aim of this study was to explore the possible role of RDW as a marker for home mechanical ventilation in real-life, unselected chronic respiratory patient populations. First, we identified characteristic RDW values for mixed case, unselected chronic respiratory failure and home mechanical ventilated patients through retrospective review within our institutional database. Next, we conducted a prospective observational study to identify RDW changes during the first six months of optimized home mechanical ventilation treatment. Adult patients starting home mechanical ventilation were included. Factors affecting RDW change during the first 6 months of treatment were analysed. RDW was elevated in both chronic respiratory failure and home mechanical ventilation patients compared to healthy individuals in the retrospective review. In the prospective study of 70 patients, we found that 55.4% of patients starting home mechanical ventilation have abnormal RDW values which are reduced from 14.7 (IQR = 13.2-16.2)% to 13.5 (IQR = 13.1-14.6)% during the first 6 months of HMV treatment (p < 0.001). RDW improvement correlates with improvement in self-reported health-related quality of life and sleepiness scale scores, as well as physical functional status during the same time frame. RDW proved to be a comparable marker to other parameters traditionally used to evaluate treatment efficacy. RDW is elevated in chronic respiratory failure patients and is significantly reduced in the first six months of optimized home mechanical ventilation. Although further research is needed to verify if RDW change reflects outcome and how comorbidities influence RDW values, our results suggest that RDW is a promising marker of home mechanical ventilation efficacy. Trial registration This study was approved by and registered at the ethics committee of Semmelweis University (TUKEB 250/2017 and TUKEB 250-1/2017, 20th of December 2017 and 1st of October 2019).
Sections du résumé
BACKGROUND
BACKGROUND
With the growing practice of home mechanical ventilation, there is a need to identify biological markers for adequate follow-up. Red cell distribution width (RDW) is a promising candidate because it is convenient, objective and may reflect treatment effect over a long period of time. The aim of this study was to explore the possible role of RDW as a marker for home mechanical ventilation in real-life, unselected chronic respiratory patient populations.
METHODS
METHODS
First, we identified characteristic RDW values for mixed case, unselected chronic respiratory failure and home mechanical ventilated patients through retrospective review within our institutional database. Next, we conducted a prospective observational study to identify RDW changes during the first six months of optimized home mechanical ventilation treatment. Adult patients starting home mechanical ventilation were included. Factors affecting RDW change during the first 6 months of treatment were analysed.
RESULTS
RESULTS
RDW was elevated in both chronic respiratory failure and home mechanical ventilation patients compared to healthy individuals in the retrospective review. In the prospective study of 70 patients, we found that 55.4% of patients starting home mechanical ventilation have abnormal RDW values which are reduced from 14.7 (IQR = 13.2-16.2)% to 13.5 (IQR = 13.1-14.6)% during the first 6 months of HMV treatment (p < 0.001). RDW improvement correlates with improvement in self-reported health-related quality of life and sleepiness scale scores, as well as physical functional status during the same time frame. RDW proved to be a comparable marker to other parameters traditionally used to evaluate treatment efficacy.
CONCLUSIONS
CONCLUSIONS
RDW is elevated in chronic respiratory failure patients and is significantly reduced in the first six months of optimized home mechanical ventilation. Although further research is needed to verify if RDW change reflects outcome and how comorbidities influence RDW values, our results suggest that RDW is a promising marker of home mechanical ventilation efficacy. Trial registration This study was approved by and registered at the ethics committee of Semmelweis University (TUKEB 250/2017 and TUKEB 250-1/2017, 20th of December 2017 and 1st of October 2019).
Identifiants
pubmed: 35354396
doi: 10.1186/s12890-022-01916-0
pii: 10.1186/s12890-022-01916-0
pmc: PMC8969261
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
115Informations de copyright
© 2022. The Author(s).
Références
Respir Res. 2007 Dec 17;8:92
pubmed: 18086309
J Thorac Dis. 2015 Oct;7(10):E402-11
pubmed: 26623117
Respir Care. 2014 Nov;59(11):1671-8
pubmed: 25233384
Oncotarget. 2017 Feb 28;8(9):16027-16035
pubmed: 27926498
Int J Chron Obstruct Pulmon Dis. 2018 Nov 01;13:3625-3634
pubmed: 30464445
Rev Port Pneumol (2006). 2016 Jul-Aug;22(4):196-201
pubmed: 26809230
Respiration. 2018;96(2):171-203
pubmed: 29945156
J Clin Med. 2019 Apr 24;8(4):
pubmed: 31022916
Sleep. 1991 Dec;14(6):540-5
pubmed: 1798888
BMC Pulm Med. 2020 May 7;20(1):130
pubmed: 32380984
Respiration. 2018;96(1):66-97
pubmed: 29945148
Respiration. 2008;75(4):418-26
pubmed: 17934248
Clin Chim Acta. 2015 Aug 25;448:107-17
pubmed: 26096256
Arch Intern Med. 2009 Mar 23;169(6):588-94
pubmed: 19307522
Clin Sci (Lond). 2009 Aug 17;117(7):251-64
pubmed: 19681758
Pediatr Cardiol. 2019 Apr;40(4):820-826
pubmed: 30830279
Transfusion. 2018 Aug;58(8):1863-1869
pubmed: 29770452
BMC Pulm Med. 2020 Aug 17;20(1):221
pubmed: 32807149
Anesthesiology. 1974 Oct;41(4):345-9
pubmed: 4412334
Heart Lung Circ. 2018 Jul;27(7):842-848
pubmed: 29107511
Chest. 2013 Jun;143(6):1692-1698
pubmed: 23238641
Diabetes Metab Syndr Obes. 2015 Oct 30;8:525-33
pubmed: 26586957
J Thorac Dis. 2018 Dec;10(12):6509-6521
pubmed: 30746195
Med Sci Monit. 2017 Dec 13;23:5899-5906
pubmed: 29233957
COPD. 2013 Aug;10(4):416-24
pubmed: 23537076
Minerva Anestesiol. 2019 Nov;85(11):1159-1167
pubmed: 30994315
Arch Bronconeumol. 2017 Mar;53(3):114-119
pubmed: 27381970
J Clin Sleep Med. 2014 Aug 15;10(8):873-8
pubmed: 25126033
Minerva Anestesiol. 2018 Jun;84(6):693-702
pubmed: 29152931
Am J Phys Med Rehabil. 2006 Feb;85(2):105-11
pubmed: 16428900
Can Respir J. 2016;2016:6547180
pubmed: 27445559
Lancet Respir Med. 2014 Sep;2(9):698-705
pubmed: 25066329
Heart Lung. 2012 May;41(3):238-43
pubmed: 21996616
Clin Respir J. 2018 Mar;12(3):1046-1052
pubmed: 28296212
Am J Cardiol. 2016 Feb 15;117(4):670-675
pubmed: 26718227
Adv Clin Chem. 2017;82:105-197
pubmed: 28939210
Thorax. 2011 May;66(5):438-45
pubmed: 20971980
Crit Rev Clin Lab Sci. 2015;52(2):86-105
pubmed: 25535770
J Neuromuscul Dis. 2014;1(1):99-109
pubmed: 27858664
PLoS One. 2018 Jan 17;13(1):e0191280
pubmed: 29342203
J Thorac Dis. 2016 Feb;8(2):255-67
pubmed: 26904266
Lung. 2016 Dec;194(6):985-995
pubmed: 27650510
Eur Respir J. 2008 Nov;32(5):1328-36
pubmed: 18579546
Lung. 2012 Jun;190(3):319-26
pubmed: 22310880
JAMA Netw Open. 2020 Sep 1;3(9):e2022058
pubmed: 32965501